Disclosures. None to declare
|
|
- Moris Johnson
- 5 years ago
- Views:
Transcription
1
2 Disclosures None to declare
3 Polling Software Interactive component using Poll Everywhere Use your smart phone to answer poll questions Text the message GEOFFB to the number If you already have Poll Everywhere app, join at PollEv.com/geoffb
4 Learning Objectives At the completion of this presentation, participants will be able to: Understand the profile of those who consume marijuana use in Ontario Know the level of evidence for use of dried cannabis for treatment of pain Know the principles of how to select an appropriate patient for use of dried cannabis for pain management Understand how to initiate, monitor, and stop the use of dried cannabis for pain management Text geoffb to number or join at PollEv.com/geoffb
5 Outline History of Medical Marijuana Regulations Profile of recreational and medical marijuana consumers Evidence for use of medical marijuana for pain control Identifying and treating neuropathic pain Initiating dried cannabis prescribing for pain control Monitoring use of dried cannabis for pain control Stopping dried cannabis therapy Prescribing and obtaining dried cannabis Caveats Text geoffb to number or join at PollEv.com/geoffb
6 Authorizing Dried Cannabis for Chronic Pain or Anxiety Preliminary Guidance document provided by the College of Family Physicians of Canada Presented September 2014 Comprehensively addresses how to manage requests for dried cannabis for chronic pain or anxiety College of Family Physicians of Canada. (2014) Authorizing Dried Cannabis for Chronic Pain or Anxiety. Retrieved from
7
8 History of Medical Marijuana Authorization in Canada Marijuana for Medical Purposes Regulations (MMPR) was initiated on April 1, 2014 Permits a physician to sign a medical document allowing patients to access a quantity of dried cannabis through a licensed producer
9 History of Medical Marijuana Authorization in Canada MMPR replaces the Marijuana Medical Access Regulations (MMAR) MMAR contained three main components Authorization to possess dried marijuana License to produce marijuana including Personal-Use Production Licenses and Designated-Person Production Licenses Access to supply of marijuana seeds or dried marijuana
10 History of Medical Marijuana Authorization in Canada MMAR were repealed on March 31, 2014 Federal Court interim injunction granted on March 21, 2014 allows individuals previously authorized to grow marijuana under MMAR to continue to do so on an interim basis
11
12 Who has encountered a patient admitting to using marijuana for recreational purposes? Marijuana is the most widely used illicit drug in Canada 10.2% of Canadians report past year use in 2012 Health Canada. (2013) Canadian Alcohol and Drug Use Monitoring Survey. Retrieved from:
13
14 Who has encountered a patient admitting to taking marijuana for medical reasons? Telephone survey of the general population in 2000 Ontario adults 18 years or older 2508 people participated Ogborne AC, Smart RG, and Adlaf EM. Self-reported medical use of marijuana: a survey of the general population. CMAJ 2000; 162 (12):
15 Who has encountered a patient admitting to taking marijuana for medical reasons? 173 (6.8%) reported marijuana use for non-medical reasons 49 (1.9%) reported marijuana use for medical reasons 2305 (91.2%) reported no use Ogborne AC, Smart RG, and Adlaf EM. Self-reported medical use of marijuana: a survey of the general population. CMAJ 2000; 162 (12):
16 Who has encountered a patient admitting to taking marijuana for medical reasons? Most frequently cited reason for using marijuana for medical purposes was for pain or nausea (41/49 or 85%) Ogborne AC, Smart RG, and Adlaf EM. Self-reported medical use of marijuana: a survey of the general population. CMAJ 2000; 162 (12):
17 Who is worried that when someone asks for marijuana for a seemingly legitimate medical reason, there might also be a component of substance misuse? Insert Poll Everywhere audience poll slide Choices are either yes or no
18
19 Who is worried that when someone asks for marijuana for a seemingly legitimate medical reason, there might also be a component of substance misuse? Gourlay DL, Heit HA. Pain and Addiction: Managing Risk Through Comprehensive Care. J Addictive Dis (3):
20 Who is worried that when someone asks for marijuana for a seemingly legitimate medical reason, there might also be a component of substance misuse? Users of marijuana for any reason tend to be younger, more likely to have alcohol problems, and more likely to have used cocaine in their lifetime Those using marijuana for medical purposes are similar to other users but more likely to have used cocaine Ogborne AC, Smart RG, and Adlaf EM. Self-reported medical use of marijuana: a survey of the general population. CMAJ 2000; 162 (12):
21 Who is worried that when someone asks for marijuana for a seemingly legitimate medical reason, there might also be a component of substance misuse? Both groups of marijuana users differed from nonusers in age, lifetime use of cocaine, and scores on the Alcohol Use Disorders Test Ogborne AC, Smart RG, and Adlaf EM. Self-reported medical use of marijuana: a survey of the general population. CMAJ 2000; 162 (12):
22
23 What condition holds the most evidence for dried cannabis use as an analgesic? No evidence to support the use of dried cannabis as a treatment for pain commonly seen in primary care (eg. Fibromyalgia, low back pain) Kahan M. Prescribing smoked cannabis for chronic noncancer pain: Preliminary recommendations. Canadian Family Physician Dec (12):
24 What condition holds the most evidence for dried cannabis use as an analgesic? 5 controlled trials have evaluated smoked cannabis in the treatment of neuropathic pain Small sample sizes Duration of trials lasted 1 to 15 days Functional status, quality of life, and other outcomes not measured Included patients who had previously smoked cannabis Kahan M. Prescribing smoked cannabis for chronic noncancer pain: Preliminary recommendations. Canadian Family Physician Dec (12):
25 Does this sound familiar? Evidence for opioid use in chronic noncancer pain Evidence of long-term efficacy for chronic, non-cancer pain (> 16 weeks) is limited and of low quality No randomized trials show long-term effectiveness of high opioid doses for chronic non-cancer pain Many patients on high doses continue to have substantial pain and related dysfunction Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: Papaleontiou M, Henderson CR, Turner BJ, Moore AA, Olkhovskaya Y, Amanfo L, Reid MC. Outcomes associated with opioid use in the treatment of chronic non-cancer pain in older adults: A systematic review and meta-analysis. JAGS ; 58: Martell BA, O Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, et al. Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med 2007; 146:
26 Pain from HIV-Associated Neuropathy Randomized placebo-controlled trial involving adults with painful HIV neuropathy Randomly assigned to smoke cannabis (3.56% THC) or placebo cigarettes Three times daily for 5 days following a standard puff procedure Primary outcome measure ratings of chronic pain and percentage achieving >30% pain relief Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen MD. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 2007; 68:
27 Pain from HIV-Associated Neuropathy Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen MD. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 2007; 68:
28 Pain from HIV-Associated Neuropathy 50 patients completed the trial Greater than 30% pain reduction reported by 52% of the cannabis group Greater than 30% reduction reported by 24% of the placebo group P = 0.04 Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen MD. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology 2007; 68:
29 Identifying Neuropathic Pain Sensory descriptions often used include burning, electric shock, tingling, cold, pricking and lancinating Screening tools The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) ID-Pain Douleur Neuropathique en 4 (DN4) PainDETECT Neuropathy Pain Scale (NPS)
30 Treating Neuropathic Pain If neuropathic pain is identified, be certain the patient has had appropriate trials of neuropathic pain agents prior to the use of dried cannabis
31 Treating Neuropathic Pain Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag Nov-Dec; 19 (6):
32 Treating Neuropathic Pain with Cannabinoids Cannabinoids have advanced to third-line agents for chronic neuropathic pain (NeP) Increasing evidence of efficacy in pain models including HIV neuropathy, post-traumatic and surgical NeP, DPNP, and spinal cord injury Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain: A systematic review of randomized trials. Br J Clin Pharmacol 2011; 72: Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain 2012; 153:
33 Treating Neuropathic Pain with Cannabinoids Canadian Neuropathic Pain Guidelines include the use of dronabinol (no longer available), oral mucosal spray, nabilone Use of dried cannabis as a therapeutic agent is included with these cannabinoids in the guidelines In contrast, Neuropathic Pain Guidelines from the International Association for the Study of Pain do not include use of dried cannabis (Jan 2015) Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag Nov-Dec; 19 (6):
34 Treating Neuropathic Pain with Cannabinoids Adequate trials of pharmaceutical cannabinoids should be trialed first Oral and buccal cannabinoids have a larger body of evidence of efficacy in the treatment of neuropathic pain Oral cannabinoids are safer, with lower risk of addiction and milder cognitive effects College of Family Physicians of Canada. (2014) Authorizing Dried Cannabis for Chronic Pain or Anxiety. Retrieved from
35 Treating Neuropathic Pain with Cannabinoids Health Canada has not reviewed data on safety or effectiveness of dried cannabis It is not approved for therapeutic use College of Family Physicians of Canada. (2014) Authorizing Dried Cannabis for Chronic Pain or Anxiety. Retrieved from
36 Initiating Dried Cannabis Therapy Unfortunately, it is impossible to determine before hand, with any degree of certainty, who will become problematic users of prescription medications. Gourlay D. Heit HA, Almahrezi A. Universal Precautions in Pain Medicine: A Rational Approach to the treatment of Chronic Pain. Pain Med (2):
37 Universal Precautions in Pain Medicine Make a diagnosis with appropriate differential Psychological assessment including risk of addictive disorders Informed consent Treatment agreement Pre- and Post- intervention assessment of pain level and function Gourlay D. Heit HA, Almahrezi A. Universal Precautions in Pain Medicine: A Rational Approach to the treatment of Chronic Pain. Pain Med (2):
38 Universal Precautions in Pain Medicine Appropriate trial of therapy +/- adjunctive medication Reassessment of pain score and level of function Regularly assess the Five A s of pain medicine Periodically review pain diagnosis and comorbid conditions, including addictive disorders Documentation Gourlay D. Heit HA, Almahrezi A. Universal Precautions in Pain Medicine: A Rational Approach to the treatment of Chronic Pain. Pain Med (2):
39 Risk of Addictive Disorders Use of screening tools to help identify at risk patients CAGE-AID Screener and Opioid Assessment for Patients with Pain (SOAPP) Opioid Risk Tool (ORT) Urine Drug Screen
40 Risk of Addictive Disorders Dried cannabis should not be prescribed in patients with a current or past cannabis use disorder Should not be prescribed with someone with an active substance use disorder
41 Cannabis Use Disorder Insists on cannabis prescriptions despite having a condition amenable to alternative treatments Uses cannabis daily or almost daily spending considerable time on this activity Poor school, work, and social functioning Addicted or misusing other substances High risk for cannabis use disorder Difficulty stopping or reducing use College of Family Physicians of Canada. (2014) Authorizing Dried Cannabis for Chronic Pain or Anxiety. Retrieved from
42 Cannabis Use Disorder Reports cannabis withdrawal symptoms after a day or more of abstinence: anxiety/fatigue Friends or family concerned about the cannabis use College of Family Physicians of Canada. (2014) Authorizing Dried Cannabis for Chronic Pain or Anxiety. Retrieved from
43 Psychological Assessment A strong association between cannabis use and mood disorders/anxiety is observed Acute cannabis use can trigger anxiety and panic attacks Cannabis use may worsen psychiatric impairments in people with anxiety disorders College of Family Physicians of Canada. (2014) Authorizing Dried Cannabis for Chronic Pain or Anxiety. Retrieved from
44 Psychological Assessment Hospital Anxiety and Depression Scale (HADS) Beck Anxiety Inventory (BAI)
45 Consent/Treatment Agreement Extensive recommendations are provided in the Preliminary Guidance Document on authorizing dried cannabis for pain or anxiety Suggestions for Harm Reduction must be discussed College of Family Physicians of Canada. (2014) Authorizing Dried Cannabis for Chronic Pain or Anxiety. Retrieved from
46 Monitoring Use of Dried Cannabis If it is being used for pain be certain it provides analgesia when used! Patients should have pain assessed before and after use Brief Pain Inventory (BPI) before and at each subsequent clinic visit can help document progress towards an analgesic or functional goal
47
48 Five A s of Analgesia Analgesia Activities of daily living Adverse effects Affect Aberrant drug-related behaviors
49 Concerns with Diversion or Misuse If diversion, stop prescribing the drug Absence of THC in the urine would be suspicious for diversion Could be difficult to identify diversion since THC can be detected in the urine for many days after use (depends on dose, chronicity of use, test cut off levels)
50 Concerns with Diversion or Misuse Authorization for cannabis should be stopped if there is suspected misuse Runs out early or uses cannabis from other sources Begins to use alcohol, opioids, or other illicit drugs problematically Shows signs of cannabis use disorder
51 Screening, Brief Intervention, and Referral to Treatment (SBIRT) An evidence-based practice used to identify, reduce, and prevent problematic use, abuse, and dependence on alcohol and illicit drugs Screening A healthcare professional assesses a patient for risky substance use using standardized tools Brief Intervention Engages the patient showing risky substance use behaviors in a short conversation, providing feedback and advice Referral to Treatment Provides a referral to brief therapy or additional treatment to patients who screen in need of additional services Bien TH, Miller WR, Tonigan JS. (1993). Brief intervention for alcohol problems: A review. Addiction, 88: Madras BK, Compton WM, Avula D et al. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: Comparison at intake and six months later. Drug and Alcohol
52 Stopping Dried Cannabis Therapy Insufficient analgesia and/or no improvement in function (BPI is helpful to identify these issues) No improvement in sleep, mood, or quality of life Impairing side effects: memory, sedation, fatigue, diminishing function Cannabis use disorder College of Family Physicians of Canada. (2014) Authorizing Dried Cannabis for Chronic Pain or Anxiety. Retrieved from
53 Prescribing Dried Cannabis Physician is required to sign a Medical Document for the Marijuana for Medical Purposes Regulations Medical Document has the format and function similar to a prescription Specify the daily quantity of dried marijuana in g/day Specify the period of use in days, weeks, or months (not to exceed 12 months)
54 Prescribing Dried Cannabis Medical Document elements: Patient name, date of birth Address where patient consulted with health practitioner Daily grams of dried marijuana, period of use Healthcare practitioner s name and administrative information Attestation by the healthcare practitioner that the information is correct and complete
55 Prescribing Dried Cannabis How much to prescribe? Guidance Document from CFPC offers comprehensive explanations regarding the recommended dosing No more than 9% THC needed according to studies this can be specified on the Medical Document Current evidence supports a daily dose of mg of dried cannabis An average joint contains 500 mg of herbal cannabis
56 Obtaining Dried Cannabis Patients can register as a client with a licensed producer of their choice Need to provide the original medical document Dried marijuana is sent to the patient directly by the licensed producer Legal possession is confirmed via the label on the marijuana package containing specific patient information or a separate document containing the same information with the shipment of marijuana
57 Caveat Emptor Wait list to obtain product can be up to 6 to 8 months Not all licensed producers supply 9% THC or less strains CFPC guidance document provides list of suppliers with 9% THC or less Clients are sometimes required to buy a minimum quantity of strain type
58 Caveat Prescriber Asking for no more than 9% THC content on the Medical Document is not enforceable patients can buy higher THC % strains if they ask for it Patient can possess either the lesser of 30 X the daily amount stipulated or 150 grams Prescriber can not further restrict the maximum allowable amount of dried cannabis
59 Caveat Prescriber - Dispensaries London Compassion Club: A dispensary located in London in operation for nearly 20 years Provides medical marijuana for symptom management Physicians must confirm they support the use of dried cannabis for symptom control before the LCC will engage with patients
60 Caveat Prescriber - Dispensaries The only legal way to obtain dried cannabis for medical use is to choose from 13 government-licensed producers LCC still operates in London but technically not legal LCC reports that source of dried cannabis is from growers previously licensed under the old MMAR
61 Learning Objectives At the completion of this presentation, participants will be able to: Understand the profile of those who consume marijuana use in Ontario Know the level of evidence for use of dried cannabis for treatment of pain Know the principles of how to select an appropriate patient for use of dried cannabis for pain management Understand how to initiate, monitor, and stop the use of dried cannabis for pain management
62 Questions
Use of Cannabinoids in Medical Practice
Use of Cannabinoids in Medical Practice Annual Scientific Assembly Family Medicine Review 2016 Murray Opdahl BSPE, MD, CCFP Objectives Briefly present: An overview of available cannabinoids Concerns voiced
More informationDr. Meldon Kahan. Women s College Hospital. with PIA LAW
with PIA LAW and Toronto ABI Network Dr. Meldon Kahan Women s College Hospital Dr. Meldon Kahan is an Associate Professor in the Department of Family Medicine at University of Toronto, and Medical Director
More informationRecent trends in medical cannabis use in Canada
Recent trends in medical cannabis use in Canada Paul Grootendorst Faculty of Pharmacy, University of Toronto Department of Economics, McMaster University Cannabis therapeutic effects Cannabis has been
More informationThe Evidence. Alex Crawley, BSP, ACPR RxFiles Academic Detailing Program
The Evidence Alex Crawley, BSP, ACPR RxFiles Academic Detailing Program Disclosure I have no relationships with commercial entities I have no real or perceived conflicts of interest I am employed by the
More informationNurse Practitioner Practice Guideline Treatment Agreements
Nurse Practitioner Practice Guideline Treatment Agreements In November 2012, the New Classes of Practitioners Regulations (NCPR) under Canada s Controlled Drug and Substances Act (CDSA) came into force,
More informationPain Management and Addiction: Clinical Challenges
Pain Management and Addiction: Clinical Challenges MMS Pain Management Forum March 12, 2010 Associate Professor of Medicine Boston University School of Medicine Boston Medical Center Conflicts of Interest
More informationCannabis for Medical Purposes
College of Physicians and Surgeons of British Columbia Cannabis for Medical Purposes Preamble This document is a standard of the Board of the College of Physicians and Surgeons of British Columbia. College
More informationUnderstanding the New Access to Cannabis for Medical Purposes Regulations
Understanding the New Access to Cannabis for Medical Purposes Regulations Health Canada August 2016 Table of Contents 1. Introduction 2. Health Canada's role 3. What it means for health care practitioners
More informationResearch: Medical Cannabis
Research: Medical Cannabis Background The hemp plant Cannabis sativa (cannabis) is commonly known as marijuana and can be used as a therapy to alleviate symptoms such as pain and fatigue caused by chronic
More informationConsumer Information Cannabis (Marihuana, marijuana)
Consumer Information Cannabis (Marihuana, marijuana) The courts in Canada have ruled that the federal government must provide reasonable access to a legal source of marijuana for medical purposes. The
More informationMedical Cannabis. Danial Schecter, MD, CCFP. Vocational Rehabilitation Association November 7th, Executive Director Cannabinoid Medical Clinic
Medical Cannabis Danial Schecter, MD, CCFP Executive Director Cannabinoid Medical Clinic Vocational Rehabilitation Association November 7th, 2014 Conflict of Interest This program has not received financial
More informationTrends in medical cannabis use in Canada,
Trends in medical cannabis use in Canada, 2001-2016 Paul Grootendorst PhD* Igor Korolija PharmD Minsup Shim PhD Leslie Dan Faculty of Pharmacy, University of Toronto *Corresponding author: paul.grootendorst@gmail.com
More informationExplanatory note for Operational Policy Manual (OPM) # , Cannabis for Medical Purposes
Medical Cannabis Explanatory note for Operational Policy Manual (OPM) #17-01-10, Cannabis for Medical Purposes WSIB Explanatory note for OPM #17-01-10, Cannabis for Medical Purposes January 2019 1 Table
More informationFaculty/Presenter Disclosure
Faculty/Presenter Disclosure Faculty: Philippe Lucas Relationships with commercial interests: Philippe Lucas is a Research Affilliate with the Centre for Addictions Research of BC, as well as VP, Patient
More informationMEMBERSHIP OVERVIEW. To become a member at Warmland, you must provide documentation confirming you fall into at least one of the following categories:
MEMBERSHIP PACKAGE MEMBERSHIP OVERVIEW Welcome to Warmland Medicinal Cannabis Centre. Our aim is to provide a consistent, safe, local and dependable source of medicinal cannabis for people suffering from
More informationLife s brighter under the sun MEDICAL CANNABIS AND GROUP BENEFITS PLAN COVERAGE
Life s brighter under the sun MEDICAL CANNABIS AND GROUP BENEFITS PLAN COVERAGE With the legalization of recreational cannabis upon us in Canada, our conversation about cannabis use is changing. It s not
More informationObjectives. 1. Review controversy 2. Pathophysiology 3. Indications for Use 4. Adverse Effects 5. How Patients Access
Medical Marijuana Deb Evans, RN, MScN, CON(C), CHPCN(C) Clinical Nurse Specialist Pain and Symptom Management Team Juravinski Cancer Centre May 29, 2014 Objectives 1. Review controversy 2. Pathophysiology
More informationVirginia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Virginia Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationAcknowledgements: What it is What it s not. Cannabis Evidence Series. Evidence-informed decision-making
Cannabis Evidence Series What it is What it s not Acknowledgements: The evidence presented is from the Cannabis evidence series authored by the HTA unit at the University of Calgary and from Rapid response
More informationCANNABIS FOR THE RHEUMATOLOGIST
CANNABIS FOR THE RHEUMATOLOGIST Dr Jagtar Singh Nijjar NIHR Clinical Lecturer in Rheumatology Disclosures None 1 Overview The history of cannabis use Anecdotal use of cannabis in chronic pain The biology
More informationPOLICY NUMBER: POL 153
Chapter: CLAIMS Subject: MEDICAL CANNABIS Effective Date: October 25, 2018 Last Update: October 25, 2018 PURPOSE STATEMENT The purpose of this policy is to explain how the Workers Compensation Board determines
More informationHealth Care Professionals Forum. May 19, 2016
Health Care Professionals Forum May 19, 2016 Statistics Update Licensed Producers There are currently 31 licenses for the production of marijuana for medical purposes There are approximately 400 applications
More informationThe Cannabis model in Canada and the USA. Dr Mark A Ware MD MRCP MSc McGill University Montreal, Quebec, Canada
The Cannabis model in Canada and the USA Dr Mark A Ware MD MRCP MSc McGill University Montreal, Quebec, Canada Outline Canada Cannabinoid medicines Existing regulatory framework Proposed new regulations
More informationMedical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center. Disclosure.
Medical Marijuana Martin P. Eason MD, JD Associate Chief of Staff for Education Mountain Home VA Medical Center Controversies in Pain Management Conference Johnson City, TN November 13, 2015 Disclosure
More informationThe Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010
The Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010 EXECUTIVE SUMMARY It is well documented in multiple
More informationA look at Marijuana in 2014
A look at Marijuana in 2014 Paul Snyder MA., LADC Overview and Objectives Discuss the mental and physical effects of marijuana use Describe the criteria for Cannabis use disorder according to the DSM 5
More informationPain, Opioids and the EMR. Dr. Gordon Schacter April 12, 2018
Pain, Opioids and the EMR Dr. Gordon Schacter April 12, 2018 Faculty/Presenter Disclosure Faculty: Gordon Schacter Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationManagement of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013
Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial
More informationMedication Management
Marina Treglia, AGPCNP BC April 4, 2019 Medication Management Identify patient criteria for risk mitigation in a medication management program at a multidisciplinary pain clinic Discuss opioid discontinuation
More informationAre We All Going to Pot?: Legal Issues Arising from Cannabis-Industry Growth The Canadian Perspective
Are We All Going to Pot?: Legal Issues Arising from Cannabis-Industry Growth The Canadian Perspective John A. Myers and Colin B. Findlay SCG Legal Annual General Meeting September 16, 2016 Boston Licensed
More informationReefer Madness version 3.0*
Reefer Madness version 3.0* Presenter Disclosure *Original Reefer Madness: FMF 2014 by R. Dubin, Sharon Cirone and Mel Kahan Update on Health Canada s MMPR and the use of cannabis for medical conditions
More informationMembership Package Checklist
Membership Package Checklist Name: Date: Phone number: Email: Please check that your membership package includes the following: Application for Registration signed and dated Code of Conduct read, checked
More informationThe 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):
Smoking Cessation Module Tobacco use is the single greatest preventable cause of chronic diseases and premature deaths worldwide. The Canadian Cancer Society reports that tobacco product use is responsible
More informationDr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina) S. Korownyk EDMONTON AB MEDICAL CANNABANOIDS IN PRIMARY CARE
Society of Rural Physicians of Canada 26TH ANNUAL RURAL AND REMOTE MEDICINE COURSE ST. JOHN'S NEWFOUNDLAND AND LABRADOR APRIL 12-14, 2018 262 Dr. G. Michael (Michael) Allan EDMONTON AB Dr. Christina (Tina)
More informationHouse of Pain? A Standardized Approach to Chronic Pain In the Patient-Centered Medical Home. MAJ Meghan Raleigh, MD 17 MAR 2014
House of Pain? A Standardized Approach to Chronic Pain In the Patient-Centered Medical Home MAJ Meghan Raleigh, MD 17 MAR 2014 Make this house your own! Objectives Review key components in PCMH Identify
More informationASPMN Conference Baltimore, Maryland
ASPMN Conference Baltimore, Maryland Prescribing Controlled Substances Managing Risk and Optimizing Outcomes September 13, 2012 Tracey Fremd, NP Tracey Fremd Consulting, Inc. Most Common Uses for Controlled
More informationThe Impaired Professional. Peter Cohen, D.O.
The Impaired Professional Peter Cohen, D.O. Definition The American Medical Association (AMA) defines impairment as the inability to practice medicine with reasonable skill and safety to patients by reason
More informationCalifornia. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationMedicinal Cannabis. Patient Log Book. Record your cannabis use and find the right dose
Medicinal Cannabis Patient Log Book Record your cannabis use and find the right dose 1 Introduction A federal system is in place for medicinal cannabis that is distinct from recreational sales. To get
More informationUniversal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids?
Learning objectives 1. Identify the contribution of psychosocial and spiritual factors to pain 2. Incorporate strategies for identifying and mitigating opioid misuse 3. Incorporate non-pharmaceutical modalities
More informationSubstance Misuse in Older People
Substance Misuse in Older People Dr Tony Rao Consultant Old Age Psychiatrist, SLAM NHS Foundation Trust Visiting Researcher, Institute of Psychiatry, Neurology and Neuroscience Chair of Substance Misuse
More informationNBPDP Drug Utilization Review Process Update
Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates
More informationMarch 12, Medical Marijuana Preliminary Consultation Online Survey Report and Analysis. Introduction:
March 12, 2014 Medical Marijuana Preliminary Consultation Online Survey Report and Analysis Introduction: The College s current Medical Marijuana policy is under review. As part of this review, the College
More informationImportant Information
Important Information Please work through the following pages with your patient or the patient s chart as necessary. Fax completed documents to 1 888 629-4722. Keep the original in your chart / file. Fee:
More informationOPIOID ANALGESICS AND STIMULANT MEDICATIONS: A Clinician Guide to Prevent Misuse
OPIOID ANALGESICS AND STIMULANT MEDICATIONS: A Clinician Guide to Prevent Misuse Advances in pharmacologic therapy have improved quality of life for patients living with pain, ADHD, and other conditions.
More informationModel. Medical Access to Marihuana first established on a case by case basis using exemptions
Table 1: Legal Framework for Cannabis in Canada Legal Framework Section 56 Exemptions under Controlled Drugs and Substances Act (1999) Marihauna Medical Access Regulations (MMAR) 2001 Marihuana for Medical
More informationTorkin Manes LegalPoint
LegalPoint JULY 2017 Marijuana and the Canadian Workplace The possession, use and sale of marijuana in Canada presently remains unlawful under the Controlled Drugs and Substances Act, but its use for medical
More informationTUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees Neuropathic Pain
1. Medical Condition Neuropathic pain is defined as pain that results from a lesion or disease in the somatosensory system. Neuropathic pain is frequently difficult to treat, and commonly interferes with
More informationNew Mexico. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile New Mexico Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationHome Phone Cell Phone
Patient Assessment Form For patients seeking ACMPR Access to Cannabis for Medical Purposes General Information First Name D.O.B YEAR MONTH DAY Last Name Gender Male Female Age If female, are you Lic. Producer
More informationCMA Response: Health Canada s Medical Marihuana Regulatory Proposal. Submitted to the Office of Controlled Substances Health Canada.
CMA Response: Health Canada s Medical Marihuana Regulatory Proposal Submitted to the Office of Controlled Substances Health Canada February 28, 2013 A healthy population and a vibrant medical profession
More informationOpioids: Use and Misuse/Steven Feinberg, MD; Scott Levy, MD, MPH, FACOEM
Western Occupational Health Conference September 14, 2012 Opioid - Use & Misuse Scott Levy, MD MPH FACOEM Steven Feinberg, MD, MPH Disclosure Information Western Occupational Health Conference 2012 Steven
More informationMedicinal Marijuana: The Canadian Journey
Medicinal Marijuana: The Canadian Journey Nady el-guebaly MD Professor & Head, Addiction Division, UofC Research Director, Alberta Gambling Research Institute Chief Examiner, ISAM Certification Disclosures:
More informationEnd the Epidemic. Miami-Dade County COMPREHENSIVE COMMUNITY PREVENTION ACTION PLAN
End the Epidemic Miami-Dade County COMPREHENSIVE COMMUNITY PREVENTION ACTION PLAN 2018 2021 Miami-Dade County along with the State of Florida and the Nation are dramatically impacted by an Opioid Epidemic
More informationColin Fetter Partner, Edmonton Office Direct: Presented by:
Colin Fetter Partner, Edmonton Office cfetter@brownleelaw.com Direct: 780-497-4867 Presented by: Introduction Medical Marijuana / Cannabis Duty to accommodate Recent case law Practical considerations Upcoming
More informationJames Donaldson CEO and Executive Director
Welcome! James Donaldson CEO and Executive Director Dr. Natasha Ryz Chief Science Officer, Zenabis Cannabis 101 Introduction to Cannabis Plant Cannabis is a genus of flowering plants within the family
More informationMarijuana strains doctor-patient relationship Jcamilobernal/iStock/Thinkstock
Early release, published at www.cmaj.ca on August 25, 2014. Subject to revision. Marijuana strains doctor-patient relationship Jcamilobernal/iStock/Thinkstock Medical marijuana is plainly bad medicine,
More informationCANNABIS LEGALIZATION: SUPPORT MATERIAL FOR MANITOBA PHYSICIANS
CANNABIS LEGALIZATION: SUPPORT MATERIAL FOR MANITOBA PHYSICIANS 1. GENERAL INFORMATION Cannabis 101 What is cannabis? Cannabis is a product derived from the Cannabis sativa plant. Cannabis contains hundreds
More informationCannabinoids: access and symptom management in cancer
Cannabinoids: access and symptom management in cancer Appetite stimulation Anecdotal reports suggest marijuana stimulates appetite AIDS/HIV dronabinol 2.5 mg bd v placebo (n=88) increase in appetite 38%
More informationAssay Sensitivity.
Assay Sensitivity Michael C. Rowbotham, MD Professor of Neurology UCSF-Mount Zion Pain Management Center Senior Scientist and IRB Chair, CPMC Research Institute Michael.Rowbotham@ucsf.edu Outline What
More informationQuality ID #414: Evaluation or Interview for Risk of Opioid Misuse National Quality Strategy Domain: Effective Clinical Care
Quality ID #414: Evaluation or Interview for Risk of Opioid Misuse National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationOklahoma. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Oklahoma Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationCanadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain
Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program New Glasgow November 1, 2017 This speaker has been asked to disclose to the audience any involvement with
More informationDisclosures. Objectives. Clearly proven risks and benefits for pain patients
The evidence for marijuana in pain management Lori Montgomery, MD CCFP Medical Director, Chronic Pain Centre Clinical Lecturer, Depts of Fam Med and Anesthesia, Disclosures Relationships with commercial
More information8 Key Findings from the 2018 Community Cannabis Survey
8 Key Findings from the 2018 Community Cannabis Survey MARCH 2019 Author Auburn Larose, Epidemiologist Planning and Evaluation Services research@healthunit.ca 1 8 Key Findings from the 2018 Community Cannabis
More informationThe Impact of Substance Use Disorders on Hospital Use
www.ccsa.ca www.cclt.ca Report in Short The Impact of Substance Use Disorders on Hospital Use What Is this Report About? This report: Describes trends in individuals hospitalized because of a primary diagnosis
More informationPatient Assessment Form
www.licencetogrow.ca info@licencetogrow.ca Patient Assessment Form PATIENT INFORMATION FIRST Name: LAST Name: Date of Birth: Address: Height: Weight: Gender: Home Phone: Email Address: SKYPE User Name:
More informationTITLE: Cannabinoids for the Management of Neuropathic Pain: Review of Clinical Effectiveness
TITLE: Cannabinoids for the Management of Neuropathic Pain: Review of Clinical Effectiveness DATE: 13 July 2010 CONTEXT AND POLICY ISSUES: Neuropathic pain is a chronic and debilitating pain syndrome that
More informationIn order to do this we want a consistent approach from Sheffield agencies to maximise the impact of this work.
The Citywide response to Spice use in Sheffield Spice use needs a co-ordinated response. Our vision is that all workers in contact with Spice users will have the opportunity to respond to Spice use in
More informationI would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people
I would like to begin by acknowledging that we are on the ancestral grounds of the Beothuk people Introduction to the Cannabinoid System And Medical Use Dr Alia Norman Radiation Oncologist Cannabinoid
More informationTreating a Patient with Cannabis Use Disorder. Disclosures. Three Areas of Focus 4/9/2018. Grants from NIDA, World Health Organization.
Treating a Patient with Cannabis Use Disorder Kevin P. Hill, M.D., M.H.S. 41 st Annual Governor s Conference on Substance Abuse, Des Moines IA 4/19/18 Division of Addiction Psychiatry, Beth Israel Deaconess
More informationRecommendations in Opioid Prescribing Guidelines for Chronic Pain
Recommendations in Opioid Prescribing Guidelines for Chronic Pain The use of opioids for treating chronic pain has been increasing. 1 In 2010, an estimated 20% of patients presenting to physician offices
More informationMedical vs Recreational Use of Cannabis. 11 th December 2017
1 Medical vs Recreational Use of Cannabis 11 th December 2017 2 Defining Cannabis and Chemical Constituents Cannabis is a plant species. Two main Cannabis sub-species are Cannabis Sativa and Cannabis Indica.
More informationPATIENT REGISTRATION Form
318 Richmond Road Ottawa, ON K1Z 6X6 p: 613-695-4923 f: 343-888-2004 e: info@hybridpharm.com PATIENT REGISTRATION Form PATIENT INFORMATION Are you applying for: Myself I am a caregiver First Name(s): Last
More informationCannabis Use Disorders: Using Evidenced Based Interventions to Engage Students in Reducing Harmful Cannabis Use or Enter Recovery
Cannabis Use Disorders: Using Evidenced Based Interventions to Engage Students in Reducing Harmful Cannabis Use or Enter Recovery Lisa Laitman MSEd, LCADC Rutgers, The State University of New Jersey National
More informationThe Sale of Cannabis in Pharmacies. Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association
The Sale of Cannabis in Pharmacies Michael H. Ghobrial, PharmD, JD Associate Director, Health Policy American Pharmacists Association Development This activity was developed by the American Pharmacists
More informationROLE PLAY #1: ASSESSMENT WITH THE 6 A s PATIENT ROLE
ROLE PLAY #1: ASSESSMENT WITH THE 6 A s PATIENT ROLE You are a 58 year old man/woman and have a history of severe chronic low back pain for 20 years. You injured your back 20 years ago at work and have
More informationAnalgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015
Analgesia for Patients with Substance Abuse Disorders Lisa Jennings CN November 2015 Definitions n Addiction: A pattern of drug use characterised by aberrant drug-taking behaviours & the compulsive use
More informationMedical Marijuana and the Workplace: Human Rights Considerations for ONA Members
Medical Marijuana and the Workplace: Human Rights Considerations for ONA Members Presented by: Pauline Lefebvre-Hinton, HRE/RTW Specialist Alyssa Lane, Legal Counsel October 2, 2018 Agenda 1. What is cannabis?
More informationMEDICAL CANNABIS PATIENT COUNSELING. Krissy Bernazani, RPh Clinical Director Zen Leaf
MEDICAL CANNABIS PATIENT COUNSELING Krissy Bernazani, RPh Clinical Director Zen Leaf DISCLOSURE Krissy Bernazani is a paid employee of Freestate Wellness, dba Zen Leaf Maryland, a medical cannabis dispensary.
More informationBased on Tip 54. Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders KAP KEYS FOR CLINICIANS
Based on Tip 54 Managing Chronic Pain in Adults With or in Recovery From Substance Use Disorders KAP KEYS FOR CLINICIANS KAP Keys Based on TIP 54 Introduction KAP Keys were developed to accompany the Treatment
More informationMedical Cannabis use in the Older Patient. Amanjot Sidhu, MD, FRCPC Division of Geriatric Medicine McMaster University
Medical Cannabis use in the Older Patient Amanjot Sidhu, MD, FRCPC Division of Geriatric Medicine McMaster University Disclosure Relationships with commercial interests: Grants/Research Support: none Speakers
More informationCADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Nabilone for Chronic Pain Management: A Review of Clinical Effectiveness and Guidelines
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Nabilone for Chronic Pain Management: A Review of Clinical Effectiveness and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication
More informationBrief Pain Inventory (Short Form)
Brief Pain Inventory (Short Form) Study ID# Hospital# Do not write above this line Date: Time: Name: Last First Middle Initial 1) Throughout our lives, most of us have had pain from time to time (such
More informationHarm Reduction Journal
Harm Reduction Journal This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon. Cannabis as a substitute
More information10 Questions to Ask. Before You Use Marijuana
10 Questions to Ask Before You Use Marijuana 1 You ve probably heard conflicting opinions about marijuana and its risks. The health information included here is based on recent studies done by researchers
More informationPEDIATRIC EXPOSURE PREVENTION
PEDIATRIC EXPOSURE PREVENTION CLINICAL GUIDANCE FOR COLORADO HEALTH CARE PROVIDERS FOR DISCUSSIONS WITH PARENTS OR GUARDIANS OF CHILDREN AND ADOLESCENTS AGES 0-20 It is illegal for Colorado youth under
More informationScreener and Opioid Assessment for Patients with Pain- Revised (SOAPP -R)
Screener and Opioid Assessment for Patients with Pain- Revised (SOAPP -R) The Screener and Opioid Assessment for Patients with Pain- Revised (SOAPP -R) is a tool for clinicians to help determine how much
More informationMedical Marijuana Use in the Workplace
By Colton Hnatiuk 201 Portage Ave, Suite 2200 Winnipeg, Manitoba R3B 3L3 1-855-483-7529 www.tdslaw.com An employee s legal ability to use cannabis for medical purposes was confirmed by the Supreme Court
More informationPATIENT QUESTIONNAIRE
PATIENT QUESTIONNAIRE Personal Information Date Name Date of Birth Age Height Weight Gender: Male / Female Address City State / Zip Home Phone Cell phone Work phone E-mail address Do you currently have
More informationPEDIATRIC EXPOSURE PREVENTION CLINICAL GUIDANCE FOR COLORADO HEALTH CARE PROVIDERS
PEDIATRIC EXPOSURE PREVENTION CLINICAL GUIDANCE FOR COLORADO HEALTH CARE PROVIDERS FOR DISCUSSIONS WITH PARENTS OR GUARDIANS OF CHILDREN AND ADOLESCENTS AGES 0-20 In Colorado, it is illegal for youth under
More informationKANSAS Kansas State Board of Healing Arts. Source: Kansas State Board of Healing Arts. Approved: October 17, 1998
KANSAS Kansas State Board of Healing Arts Source: Kansas State Board of Healing Arts Approved: October 17, 1998 GUIDELINES FOR THE USE OF CONTROLLED SUBSTANCES FOR THE TREATMENT OF PAIN Section 1: Preamble
More informationIs there a role for medical marijuana in the management of IBD? Jami A. Kinnucan, MD Division of Gastroenterology University of Michigan Hospital
Is there a role for medical marijuana in the management of IBD? Jami A. Kinnucan, MD Division of Gastroenterology University of Michigan Hospital Disclosures No relevant financial or relationship disclosures
More informationMANAGING MEDICAL & RECREATIONAL CANNABIS IN THE WORKPLACE
MANAGING MEDICAL & RECREATIONAL CANNABIS IN THE WORKPLACE 1 CONTENTS While medical cannabis has been legal for some time, on October 17, 2018, recreational cannabis became legal in Canada. This rapid change
More informationImportant Information
Important Information Please work through the following pages with your patient or the patient s chart as necessary. Fax completed documents to 1 888 629-4722. Keep the original in your chart / file. Fee:
More informationMinnesota. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Minnesota Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points
More informationMedical Marijuana: The Move to Schedule II
Medical Marijuana: The Move to Schedule II David Deitz, MD, PhD David Deitz & Associates Today s discussion Does medical marijuana actually treat anything? What are the workplace issues? What are the interactions
More informationVermont. Prescribing and Dispensing Profile. Research current through November 2015.
Prescribing and Dispensing Profile Vermont Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points of
More informationCANADIAN CANNABIS CRAZE (AND CONUNDRUM) Dr. Melissa Snider-Adler Chief Medical Review Officer DriverCheck Inc. Addiction Medicine Physician
CANADIAN CANNABIS CRAZE (AND CONUNDRUM) Dr. Melissa Snider-Adler Chief Medical Review Officer DriverCheck Inc. Addiction Medicine Physician AGENDA THC IMPAIRMENT A deep dive into THC vs. CBD Signs and
More informationWHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis. Expert Peer Review 2
WHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis Expert Peer Review 2 1. Comments based on the review report a. Evidence on dependence and abuse potential Extracts
More information